Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry. 

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry.